Does Florida Blue (Blue Cross Blue Shield of Florida) Cover Dupixent?

What Is Dupixent and Why Does Coverage Complexity Matter?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 (IL-4) and interleukin-13 (IL-13), two cytokines central to type 2 inflammatory disease. The FDA first approved dupilumab in March 2017 for moderate-to-severe atopic dermatitis in adults, and the label has since expanded to cover six additional indications across multiple organ systems. [1]

Because Dupixent carries a list price near $3,800 per month, insurers including Florida Blue classify it as a specialty-tier biologic. That tier placement triggers automatic prior authorization requirements regardless of which Florida Blue plan you hold, whether commercial, Medicare Advantage, or Marketplace.

The Biological Rationale Behind Dupixent

IL-4 and IL-13 drive the type 2 immune response responsible for the itch-scratch cycle in atopic dermatitis, airway hyperresponsiveness in asthma, and polyp formation in chronic rhinosinusitis. Dupilumab binds the IL-4Rα subunit, blocking both pathways simultaneously. [2]

The key SOLO 1 and SOLO 2 trials (combined N=1,379) demonstrated that 16 mg/kg dupilumab produced an IGA 0/1 (clear or almost clear skin) response in 37% to 38% of adults with moderate-to-severe atopic dermatitis at week 16, compared with 8% to 10% for placebo (P<0.001). [3] That level of efficacy, combined with a favorable safety profile, drove widespread dermatology guideline endorsement.

Why Florida Blue Requires Prior Authorization

The American Academy of Dermatology 2023 guidelines recommend dupilumab as a first-line systemic agent for adults with moderate-to-severe atopic dermatitis who fail topical therapy. [4] Florida Blue's medical policy, however, follows a step-edit approach that requires documented failure of at least one conventional systemic agent such as cyclosporine, methotrexate, or azathioprine before approving dupilumab, except for indications where step therapy is clinically inappropriate or contraindicated.

This gatekeeping exists because specialty biologics account for a disproportionate share of pharmacy spend. A 2023 IQVIA report noted that specialty drugs represented roughly 55% of total drug spending in the United States despite accounting for only about 2% of prescriptions. [5]

Which Dupixent Indications Does Florida Blue Typically Cover?

Florida Blue's formulary covers Dupixent for all current FDA-approved indications, provided the member meets the plan's specific clinical criteria for each indication. The coverage criteria differ by condition.

Atopic Dermatitis

For adults and adolescents 12 years and older, Florida Blue typically requires:

• A diagnosis of moderate-to-severe atopic dermatitis confirmed by a dermatologist
• Documented inadequate response, intolerance, or contraindication to at least one conventional systemic agent
• Baseline Eczema Area and Severity Index (EASI) score or Investigator Global Assessment (IGA) documenting moderate-to-severe disease

For children ages 6 months to 11 years, the FDA approved dupilumab based on the LIBERTY AD PEDS trial showing a 27% IGA 0/1 response at week 16 for dupilumab versus 4% for placebo in the 6-to-11 age cohort (P<0.001). [6] Florida Blue generally mirrors FDA labeling for pediatric coverage but may require additional documentation from a board-certified pediatric dermatologist.

Asthma

For moderate-to-severe eosinophilic asthma or oral corticosteroid-dependent asthma, the LIBERTY ASTHMA QUEST trial (N=1,902) showed dupilumab 200 mg every 2 weeks reduced annualized severe exacerbation rates by 47.7% in patients with baseline blood eosinophil counts of 300 cells/µL or higher. [7] Florida Blue typically requires documented failure of inhaled corticosteroid/long-acting beta agonist combination therapy and a baseline blood eosinophil count or FeNO result.

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

The SINUS-24 and SINUS-52 trials (combined N=724) showed dupilumab reduced nasal polyp score by a mean of 2.06 points versus 0.28 for placebo at week 24 (P<0.001). [8] Florida Blue usually requires prior sinus surgery or documented contraindication to surgery plus inadequate response to nasal corticosteroids.

Eosinophilic Esophagitis (EoE)

The LIBERTY EoE TREET Part A and B trials showed dupilumab 300 mg weekly produced histologic remission (peak eosinophil count <6/hpf) in 47% of patients versus 6% for placebo at week 24. [9] Coverage criteria typically include confirmed EoE diagnosis by esophageal biopsy and documented dietary elimination or proton pump inhibitor failure.

Prurigo Nodularis

The PRIME and PRIME2 trials (combined N=406) showed dupilumab 300 mg every 2 weeks achieved a 0 or 1 IGA score with a 4-point improvement in 37% of patients at week 24 versus 22% for placebo. [10] Florida Blue generally requires prior failure of topical agents or systemic immunosuppressants.

COPD with Type 2 Inflammation

The FDA approved dupilumab for uncontrolled COPD with type 2 inflammation in June 2024, based on the BOREAS trial (N=939) which showed a 34% reduction in moderate-to-severe COPD exacerbations versus placebo (P<0.001). [11] Florida Blue's coverage criteria for this newer indication may still be in development or may require appeal; members should verify current formulary status directly with Florida Blue.

How to Get Prior Authorization Approved for Dupixent Through Florida Blue

Prior authorization is the biggest barrier to Dupixent access. A systematic approach dramatically improves first-attempt approval rates.

Step 1: Gather Required Documentation

Your prescribing physician needs to submit the following before initiating the authorization request:

• Signed prescription and letter of medical necessity on clinic letterhead
• Office notes documenting disease severity scores (EASI, IGA, ACQ, NPS, or equivalent)
• Lab results supporting the indication (eosinophil count for asthma/COPD, biopsy report for EoE)
• Documentation of prior treatment failures with dates, doses, and reason for discontinuation
• ICD-10 diagnosis codes appropriate to the indication

The more specific the documentation, the less likely the insurer is to issue a peer-to-peer review delay. A 2022 survey published in the Journal of the American Academy of Dermatology found that incomplete prior authorization submissions accounted for 43% of initial denials for biologic dermatologic therapies. [12]

Step 2: Submit Through Florida Blue's Provider Portal

Florida Blue uses the Availity portal for electronic prior authorization submissions. Turnaround times for specialty biologics typically run 3 to 14 business days for standard review. Urgent requests, where clinical circumstances justify expedited review, must be processed within 72 hours under Florida state law.

Step 3: Request a Peer-to-Peer Review If Denied

If Florida Blue issues an initial denial, the prescribing physician can request a peer-to-peer telephone review with the plan's medical director within 5 to 10 business days of the denial notice. Peer-to-peer reviews resolve a meaningful proportion of initial denials without requiring a formal appeal.

Step 4: File a Formal Appeal

Florida state law, under Florida Statute 627.6131, gives members the right to a first-level internal appeal, a second-level internal appeal, and then an external independent review. The external review process is conducted by a state-certified independent review organization (IRO) and carries binding authority over the insurer.

The HealthRX Prior Authorization Decision Framework for Dupixent (see graphic) maps the documentation pathway from initial submission through IRO external review, including the specific clinical evidence thresholds that have historically converted denials to approvals across each Dupixent indication.

Understanding Florida Blue's Step Therapy Requirements for Dupixent

Step therapy, sometimes called "fail first," means Florida Blue requires proof that a member has already tried and failed on less expensive treatments before approving Dupixent.

Atopic Dermatitis Step Therapy

For atopic dermatitis, Florida Blue typically requires documented failure of:

1. High-potency topical corticosteroids (e.g., clobetasol propionate 0.05% cream for at least 4 weeks)
2. At least one conventional systemic immunosuppressant such as cyclosporine 3-5 mg/kg/day, methotrexate 10-25 mg/week, or mycophenolate mofetil 1-3 g/day

Topical calcineurin inhibitors (tacrolimus, pimecrolimus) may be accepted as additional step evidence.

The step therapy requirement can be waived if the conventional systemic is contraindicated. Cyclosporine, for instance, is contraindicated in patients with uncontrolled hypertension, significantly impaired renal function (eGFR <50 mL/min/1.73m²), or active malignancy. [13] A physician attestation of contraindication, supported by relevant lab values or clinical notes, typically satisfies the step therapy requirement in these cases.

Asthma Step Therapy

For asthma, Florida Blue generally requires:

• Documentation of current or prior use of medium-to-high dose inhaled corticosteroid (ICS) plus long-acting beta agonist (LABA)
• Blood eosinophil count of 300 cells/µL or higher, or fractional exhaled nitric oxide (FeNO) of 25 ppb or higher, supporting type 2 phenotype
• Spirometry results confirming airflow obstruction (FEV1 <80% predicted)

When Step Therapy Can Be Bypassed

Florida's Patients First Act (Florida Statute 627.42393), enacted in 2019, restricts insurer-mandated step therapy when it would cause serious harm, when the required drug is contraindicated, or when the patient has already failed the required drug prior to enrolling in the current plan. [14] Physicians should reference this statute explicitly in appeals letters when step therapy requirements are clinically inappropriate.

Dupixent Costs Under Florida Blue: What to Expect

Even with coverage approved, out-of-pocket costs can be significant under a specialty tier structure.

Formulary Tier Placement and Cost-Sharing

Florida Blue places Dupixent on Tier 4 or Tier 5 (specialty) across most commercial plan designs. Depending on the specific plan, specialty tier cost-sharing may involve:

• A coinsurance rate of 20% to 40% of the negotiated drug cost
• A specialty deductible that must be satisfied before cost-sharing begins
• An annual out-of-pocket maximum that caps total member spending

The negotiated rate Florida Blue pays for Dupixent is confidential, but it is substantially below the list price of approximately $3,800 per month. After negotiated discounts and rebates, member coinsurance is typically calculated on the plan's allowed amount rather than the list price.

Sanofi/Regeneron Dupixent MyWay Program

Commercially insured patients who are not covered by a government-funded program (Medicare, Medicaid, TRICARE) may qualify for the Dupixent MyWay copay card, which can reduce out-of-pocket costs to as low as $0 per month for eligible patients. The program covers up to $13,000 per year in cost-sharing. [15]

Patients can enroll at dupixent.com or by calling 1-844-DUPIXENT. Eligibility is confirmed at the time of enrollment.

Medicare Advantage Members

Florida Blue administers several Medicare Advantage plans in Florida. Medicare Advantage members who use Dupixent should be aware that the Inflation Reduction Act of 2022 caps Medicare Part D out-of-pocket drug costs at $2,000 annually starting in 2025. [16] Additionally, the Sanofi/Regeneron copay assistance card cannot be used for Medicare-covered benefits, but the Dupixent Patient Assistance Program (PAP) may cover costs for Medicare beneficiaries below certain income thresholds.

Medicaid (Florida Medicaid)

Florida Medicaid is a separate program from Florida Blue. Medicaid members should check with the Agency for Health Care Administration (AHCA) formulary or their specific managed Medicaid plan. Dupixent is covered under Florida Medicaid for FDA-approved indications with prior authorization, but step therapy requirements and documentation standards may differ from commercial Florida Blue plans.

How Florida Blue's Medical Policy for Dupixent Compares to National Guidelines

Clinical guidelines and insurer medical policies do not always align perfectly. Understanding the gaps helps physicians write stronger authorization requests.

AAD and AAFA Guideline Positions

The American Academy of Dermatology (AAD) 2023 guidelines state that dupilumab is "recommended as a first-line systemic therapy for adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy." [4] The guidelines do not require prior failure of conventional systemics as a clinical prerequisite.

The Asthma and Allergy Foundation of America (AAFA) supports dupilumab use in patients with uncontrolled moderate-to-severe asthma with an eosinophilic phenotype as add-on maintenance therapy. [17]

The Gap Between Guidelines and Policy

Florida Blue's medical policy imposes step therapy requirements that are stricter than AAD recommendations. A physician advocacy letter that directly quotes the AAD guideline language and explains why conventional systemics are contraindicated or clinically inappropriate for a specific patient can be an effective tool in closing this gap during the appeal process.

The Journal of the American Academy of Dermatology published a 2021 analysis showing that step therapy requirements for biologic dermatologic agents delayed appropriate treatment initiation by a mean of 9.7 months in patients who were ultimately approved. [18] This delay data can be cited in medical necessity letters to support urgency.

What Happens If Florida Blue Denies Dupixent Coverage?

Denial does not mean the answer is final. A structured appeal process and alternative access pathways exist.

Internal Appeal Process

After an initial denial, Florida Blue must provide a written explanation of the denial reason and instructions for appeal. The internal appeal timeline under Florida law is:

• First-level internal appeal: decision within 30 days for standard requests, 72 hours for urgent
• Second-level internal appeal (if available): same timelines apply

Submitting additional clinical documentation with the appeal, including peer-reviewed literature supporting the indication and a physician attestation, strengthens the record. The SOLO 1, SOLO 2, and LIBERTY trial data cited above are directly relevant supporting evidence. [3, 6, 7]

External Independent Review

If internal appeals fail, Florida members may request external review through the Florida Department of Financial Services. The external reviewer is an independent organization not affiliated with Florida Blue, and the decision is binding on the insurer under Florida Statute 627.6131. [19]

Patient Assistance During the Appeals Period

During the appeals process, patients can apply for the Dupixent Patient Assistance Program directly through Sanofi/Regeneron if they meet income criteria, or request free medication through physician samples if available. Specialty pharmacies such as Optum Specialty Pharmacy, which distributes Dupixent, sometimes have bridge supply programs for patients awaiting prior authorization decisions.

Practical Steps for Florida Blue Members Starting Dupixent

Getting from prescription to first injection involves several coordinated steps.

Work With a Specialty Pharmacy

Dupixent is dispensed exclusively through specialty pharmacies. Florida Blue contracts with specific in-network specialty pharmacies; using an out-of-network specialty pharmacy may result in significantly higher cost-sharing or no coverage. Confirm the specific preferred specialty pharmacy with Florida Blue before the prescription is sent.

Verify the Prior Authorization Status Before Injecting

Do not inject a dose until the prior authorization is confirmed in writing and the specialty pharmacy has verified coverage. Injecting before PA confirmation can result in the claim being denied as unauthorized.

Set Up Injection Training

Dupixent is available as a 300 mg prefilled syringe or autoinjector for subcutaneous administration. The prescribing physician's office or the specialty pharmacy can arrange injection training. The Dupixent MyWay program also provides nurse support for patients initiating therapy. [15]

Monitor and Renew the Prior Authorization

Prior authorizations for Dupixent through Florida Blue are typically approved for 12 months and require renewal. The renewal requires documentation showing the patient has responded to treatment. Ophthalmologic side effects including conjunctivitis occur in roughly 10% to 28% of atopic dermatitis patients treated with dupilumab in clinical trials. [20] Documenting that side effects are managed and the patient continues to benefit supports renewal approval.